GB201513921D0 - Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers - Google Patents

Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers

Info

Publication number
GB201513921D0
GB201513921D0 GBGB1513921.5A GB201513921A GB201513921D0 GB 201513921 D0 GB201513921 D0 GB 201513921D0 GB 201513921 A GB201513921 A GB 201513921A GB 201513921 D0 GB201513921 D0 GB 201513921D0
Authority
GB
United Kingdom
Prior art keywords
peptides
cancers
combination
prostate cancer
immunotherapy against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1513921.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immatics Biotechnologies GmbH
Original Assignee
Immatics Biotechnologies GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54200350&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB201513921(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immatics Biotechnologies GmbH filed Critical Immatics Biotechnologies GmbH
Publication of GB201513921D0 publication Critical patent/GB201513921D0/en
Priority to AU2016303021A priority Critical patent/AU2016303021B2/en
Priority to MA46022A priority patent/MA46022B1/fr
Priority to PE2018000178A priority patent/PE20180695A1/es
Priority to CR20200435A priority patent/CR20200435A/es
Priority to DK16750766.4T priority patent/DK3331900T3/da
Priority to PCT/EP2016/068727 priority patent/WO2017021527A2/en
Priority to PL16750766T priority patent/PL3331900T3/pl
Priority to SI201631144T priority patent/SI3331900T1/sl
Priority to PE2023002284A priority patent/PE20250557A1/es
Priority to EP23216403.8A priority patent/EP4324472A3/en
Priority to CN201680045204.4A priority patent/CN107849107A/zh
Priority to IL310078A priority patent/IL310078A/en
Priority to TW112150529A priority patent/TW202415673A/zh
Priority to RS20210446A priority patent/RS61713B1/sr
Priority to EP16750766.4A priority patent/EP3331900B1/en
Priority to KR1020187005514A priority patent/KR102943979B1/ko
Priority to MDE20180586T priority patent/MD3331900T2/ro
Priority to SG10202001660YA priority patent/SG10202001660YA/en
Priority to BR112018001687-0A priority patent/BR112018001687A2/pt
Priority to CN202111376484.6A priority patent/CN114395013A/zh
Priority to MYPI2020006864A priority patent/MY200281A/en
Priority to CR20200434A priority patent/CR20200434A/es
Priority to EP20216899.3A priority patent/EP3854801A3/en
Priority to CA3110640A priority patent/CA3110640A1/en
Priority to MYPI2020006865A priority patent/MY203318A/en
Priority to CR20200432A priority patent/CR20200432A/es
Priority to EA201890440A priority patent/EA201890440A1/ru
Priority to ES16750766T priority patent/ES2862400T3/es
Priority to LTEP16750766.4T priority patent/LT3331900T/lt
Priority to MA053452A priority patent/MA53452A/fr
Priority to EP20216870.4A priority patent/EP3842446A1/en
Priority to TW105124943A priority patent/TWI829618B/zh
Priority to US15/229,970 priority patent/US9908920B2/en
Priority to CR20180074A priority patent/CR20180074A/es
Priority to MX2018001421A priority patent/MX2018001421A/es
Priority to JP2018505723A priority patent/JP6884752B2/ja
Priority to CR20200433A priority patent/CR20200433A/es
Priority to TW109124889A priority patent/TW202106702A/zh
Priority to CR20200431A priority patent/CR20200431A/es
Priority to UAA201800448A priority patent/UA125816C2/uk
Priority to CA2994771A priority patent/CA2994771C/en
Priority to HUE16750766A priority patent/HUE053657T2/hu
Priority to HRP20210709TT priority patent/HRP20210709T8/hr
Priority to CA3110633A priority patent/CA3110633A1/en
Priority to MA053680A priority patent/MA53680A/fr
Priority to PT167507664T priority patent/PT3331900T/pt
Priority to MA41879A priority patent/MA41879A1/fr
Priority to MYPI2018700247A priority patent/MY202812A/en
Priority to US15/638,072 priority patent/US10155032B2/en
Priority to US15/637,906 priority patent/US9993539B2/en
Priority to US15/849,878 priority patent/US10500259B2/en
Priority to ZA2018/00513A priority patent/ZA201800513B/en
Priority to PH12018500189A priority patent/PH12018500189A1/en
Priority to MX2021015933A priority patent/MX2021015933A/es
Priority to IL257331A priority patent/IL257331A/en
Priority to CL2018000324A priority patent/CL2018000324A1/es
Priority to CONC2018/0002202A priority patent/CO2018002202A2/es
Priority to US16/100,498 priority patent/US10383930B2/en
Priority to US16/153,294 priority patent/US10238727B2/en
Priority to US16/210,330 priority patent/US10376568B2/en
Priority to US16/385,221 priority patent/US10449238B2/en
Priority to US16/385,225 priority patent/US10478480B2/en
Priority to US16/507,375 priority patent/US10532091B1/en
Priority to US16/552,873 priority patent/US10799569B2/en
Priority to US16/915,465 priority patent/US11058754B2/en
Priority to US17/017,281 priority patent/US11065315B2/en
Priority to JP2020191407A priority patent/JP7142957B2/ja
Priority to CY20211100164T priority patent/CY1123854T1/el
Priority to AU2021202056A priority patent/AU2021202056B2/en
Priority to AU2021202060A priority patent/AU2021202060B2/en
Priority to AU2021202059A priority patent/AU2021202059B2/en
Priority to AU2021202058A priority patent/AU2021202058B2/en
Priority to AU2021202057A priority patent/AU2021202057B2/en
Priority to US17/320,878 priority patent/US20210275653A1/en
Priority to US17/320,938 priority patent/US11826409B2/en
Priority to US17/320,929 priority patent/US11786584B2/en
Priority to CL2021001544A priority patent/CL2021001544A1/es
Priority to CL2021001545A priority patent/CL2021001545A1/es
Priority to CL2021001542A priority patent/CL2021001542A1/es
Priority to CL2021001543A priority patent/CL2021001543A1/es
Priority to CL2021001744A priority patent/CL2021001744A1/es
Priority to US17/576,185 priority patent/US12076381B2/en
Priority to US17/576,067 priority patent/US12102670B2/en
Priority to US17/581,054 priority patent/US20220143163A1/en
Priority to US17/581,049 priority patent/US12097249B2/en
Priority to US17/587,474 priority patent/US12180259B2/en
Priority to US17/587,536 priority patent/US12144852B2/en
Priority to US17/592,573 priority patent/US20220152175A1/en
Priority to JP2022142129A priority patent/JP2022191218A/ja
Priority to CL2022003264A priority patent/CL2022003264A1/es
Priority to AU2023204661A priority patent/AU2023204661A1/en
Priority to US18/451,216 priority patent/US20240016908A1/en
Priority to AU2023233214A priority patent/AU2023233214A1/en
Priority to JP2024215091A priority patent/JP2025038025A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
GBGB1513921.5A 2015-08-05 2015-08-06 Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers Ceased GB201513921D0 (en)

Priority Applications (94)

Application Number Priority Date Filing Date Title
AU2016303021A AU2016303021B2 (en) 2015-08-05 2016-08-05 Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
MA46022A MA46022B1 (fr) 2015-08-05 2016-08-05 Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de la prostate et d'autres cancers
PE2018000178A PE20180695A1 (es) 2015-08-05 2016-08-05 Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de prostata y otros tipos de cancer
CR20200435A CR20200435A (es) 2015-08-05 2016-08-05 Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer (div. 4. 2018-74)
DK16750766.4T DK3331900T3 (da) 2015-08-05 2016-08-05 Peptider og kombination af peptider til anvendelse ved immunterapi mod prostatacancer og andre cancere
PCT/EP2016/068727 WO2017021527A2 (en) 2015-08-05 2016-08-05 Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
PL16750766T PL3331900T3 (pl) 2015-08-05 2016-08-05 Peptydy i kombinacja peptydów do stosowania w immunoterapii przeciwko rakowi gruczołu krokowego i innym nowotworom
SI201631144T SI3331900T1 (sl) 2015-08-05 2016-08-05 Peptidi in kombinacija peptidov za uporabo v imunoterapiji proti raku prostate in drugim oblikam raka
PE2023002284A PE20250557A1 (es) 2015-08-05 2016-08-05 Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de prostata y otros tipos de cancer
EP23216403.8A EP4324472A3 (en) 2015-08-05 2016-08-05 Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
CN201680045204.4A CN107849107A (zh) 2015-08-05 2016-08-05 用于前列腺癌和其他癌症免疫治疗的新型肽和肽组合物
IL310078A IL310078A (en) 2015-08-05 2016-08-05 New peptides and combinations of peptides for use in immunotherapy against prostate cancer and other types of cancer
TW112150529A TW202415673A (zh) 2015-08-05 2016-08-05 用於攝護腺癌和其他癌症免疫治療的新型肽和肽組合物
RS20210446A RS61713B1 (sr) 2015-08-05 2016-08-05 Peptidi i kombinacija peptida za upotrebu u imunoterapiji protiv raka prostate i drugih malignih tumora
EP16750766.4A EP3331900B1 (en) 2015-08-05 2016-08-05 Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
KR1020187005514A KR102943979B1 (ko) 2015-08-05 2016-08-05 전립선암 및 기타 암에 대한 면역요법에서의 사용을 위한 펩티드 및 펩티드의 조합
MDE20180586T MD3331900T2 (ro) 2015-08-05 2016-08-05 Peptide și combinație de peptide pentru utilizare în imunoterapie împotriva cancerului de prostată și altor cancere
SG10202001660YA SG10202001660YA (en) 2015-08-05 2016-08-05 Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
BR112018001687-0A BR112018001687A2 (pt) 2015-08-05 2016-08-05 peptídeos e combinações de peptídeos para uso na imunoterapia contra o câncer de próstata e outros cânceres
CN202111376484.6A CN114395013A (zh) 2015-08-05 2016-08-05 用于前列腺癌和其他癌症免疫治疗的新型肽和肽组合物
MYPI2020006864A MY200281A (en) 2015-08-05 2016-08-05 Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
CR20200434A CR20200434A (es) 2015-08-05 2016-08-05 Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer (div. 5. 2018-74)
EP20216899.3A EP3854801A3 (en) 2015-08-05 2016-08-05 Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
CA3110640A CA3110640A1 (en) 2015-08-05 2016-08-05 Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
MYPI2020006865A MY203318A (en) 2015-08-05 2016-08-05 Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
CR20200432A CR20200432A (es) 2015-08-05 2016-08-05 Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer (div. 2. 2018-74)
EA201890440A EA201890440A1 (ru) 2015-08-05 2016-08-05 Новые пептиды и комбинации пептидов для применения в иммунотерапии рака предстательной железы и других видов рака
ES16750766T ES2862400T3 (es) 2015-08-05 2016-08-05 Péptidos y combinaciones de péptidos para su uso en inmunoterapia contra el cáncer de próstata y otros cánceres
LTEP16750766.4T LT3331900T (lt) 2015-08-05 2016-08-05 Peptidai ir peptidų derinys, skirti naudoti imunoterapijai gydant prostatos vėžį ir kitų rūšių vėžį
MA053452A MA53452A (fr) 2015-08-05 2016-08-05 Peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de la prostate et d'autres cancers
EP20216870.4A EP3842446A1 (en) 2015-08-05 2016-08-05 Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
TW105124943A TWI829618B (zh) 2015-08-05 2016-08-05 用於攝護腺癌和其他癌症免疫治療的新型肽和肽組合物
US15/229,970 US9908920B2 (en) 2015-08-05 2016-08-05 Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
CR20180074A CR20180074A (es) 2015-08-05 2016-08-05 Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer
MX2018001421A MX2018001421A (es) 2015-08-05 2016-08-05 Peptidos y combinacion de peptidos para usarse en la inmunoterapia contra el cancer de prostata y otros tipos de cancer.
JP2018505723A JP6884752B2 (ja) 2015-08-05 2016-08-05 前立腺がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
CR20200433A CR20200433A (es) 2015-08-05 2016-08-05 Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer (div. 3. 2018-74)
TW109124889A TW202106702A (zh) 2015-08-05 2016-08-05 用於攝護腺癌和其他癌症免疫治療的新型肽和肽組合物
CR20200431A CR20200431A (es) 2015-08-05 2016-08-05 Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer (div. 1. 2018-74)
UAA201800448A UA125816C2 (uk) 2015-08-05 2016-08-05 Пептид, придатний для лікування та/або діагностики раку
CA2994771A CA2994771C (en) 2015-08-05 2016-08-05 Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
HUE16750766A HUE053657T2 (hu) 2015-08-05 2016-08-05 Peptidek és peptidkombinációk a prosztatarák és más ráktípusok elleni immunterápiában történõ használatra
HRP20210709TT HRP20210709T8 (hr) 2015-08-05 2016-08-05 Peptidi i kombinacija peptida za imunoterapiju protiv karcinoma prostate i druge vrste karcinoma
CA3110633A CA3110633A1 (en) 2015-08-05 2016-08-05 Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
MA053680A MA53680A (fr) 2015-08-05 2016-08-05 Peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de la prostate et d'autres cancers
PT167507664T PT3331900T (pt) 2015-08-05 2016-08-05 Péptidos e combinação de péptidos para uso em imunoterapia do cancro da próstata e outros cancros
MA41879A MA41879A1 (fr) 2015-08-05 2016-08-05 Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de la prostate et d'autres cancers
MYPI2018700247A MY202812A (en) 2015-08-05 2016-08-05 Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
US15/638,072 US10155032B2 (en) 2015-08-05 2017-06-29 Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
US15/637,906 US9993539B2 (en) 2015-08-05 2017-06-29 Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
US15/849,878 US10500259B2 (en) 2015-08-05 2017-12-21 Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
ZA2018/00513A ZA201800513B (en) 2015-08-05 2018-01-24 Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
PH12018500189A PH12018500189A1 (en) 2015-08-05 2018-01-25 Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
MX2021015933A MX2021015933A (es) 2015-08-05 2018-02-01 Peptidos y combinacion de peptidos para usarse en la inmunoterapia contra el cancer de prostata y otros tipos de cancer.
IL257331A IL257331A (en) 2015-08-05 2018-02-04 Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
CL2018000324A CL2018000324A1 (es) 2015-08-05 2018-02-05 Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer
CONC2018/0002202A CO2018002202A2 (es) 2015-08-05 2018-02-27 Péptidos y combinaciones de péptidos para inmunoterapia contra el cáncer de próstata y otros tipos de cáncer
US16/100,498 US10383930B2 (en) 2015-08-05 2018-08-10 Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
US16/153,294 US10238727B2 (en) 2015-08-05 2018-10-05 Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
US16/210,330 US10376568B2 (en) 2015-08-05 2018-12-05 Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
US16/385,221 US10449238B2 (en) 2015-08-05 2019-04-16 Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
US16/385,225 US10478480B2 (en) 2015-08-05 2019-04-16 Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
US16/507,375 US10532091B1 (en) 2015-08-05 2019-07-10 Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
US16/552,873 US10799569B2 (en) 2015-08-05 2019-08-27 Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
US16/915,465 US11058754B2 (en) 2015-08-05 2020-06-29 Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
US17/017,281 US11065315B2 (en) 2015-08-05 2020-09-10 Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
JP2020191407A JP7142957B2 (ja) 2015-08-05 2020-11-18 前立腺がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
CY20211100164T CY1123854T1 (el) 2015-08-05 2021-02-26 Πεπτιδια και συνδυασμος πεπτιδιων για χρηση στην ανοσοθεραπεια εναντι του καρκινου του προστατη και αλλων καρκινων
AU2021202056A AU2021202056B2 (en) 2015-08-05 2021-04-01 Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
AU2021202060A AU2021202060B2 (en) 2015-08-05 2021-04-01 Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
AU2021202059A AU2021202059B2 (en) 2015-08-05 2021-04-01 Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
AU2021202058A AU2021202058B2 (en) 2015-08-05 2021-04-01 Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
AU2021202057A AU2021202057B2 (en) 2015-08-05 2021-04-01 Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
US17/320,878 US20210275653A1 (en) 2015-08-05 2021-05-14 Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
US17/320,938 US11826409B2 (en) 2015-08-05 2021-05-14 Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
US17/320,929 US11786584B2 (en) 2015-08-05 2021-05-14 Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
CL2021001544A CL2021001544A1 (es) 2015-08-05 2021-06-11 Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer (divisional de la solicitud no. 201800324)
CL2021001545A CL2021001545A1 (es) 2015-08-05 2021-06-11 Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer (divisional de la solicitud no. 201800324)
CL2021001542A CL2021001542A1 (es) 2015-08-05 2021-06-11 Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer (divisional de la solicitud no. 201800324)
CL2021001543A CL2021001543A1 (es) 2015-08-05 2021-06-11 Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer (divisional de la solicitud no. 201800324)
CL2021001744A CL2021001744A1 (es) 2015-08-05 2021-06-30 Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer (divisional de la solicitud no. 201800324)
US17/576,185 US12076381B2 (en) 2015-08-05 2022-01-14 Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
US17/576,067 US12102670B2 (en) 2015-08-05 2022-01-14 Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
US17/581,054 US20220143163A1 (en) 2015-08-05 2022-01-21 Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
US17/581,049 US12097249B2 (en) 2015-08-05 2022-01-21 Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
US17/587,474 US12180259B2 (en) 2015-08-05 2022-01-28 Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
US17/587,536 US12144852B2 (en) 2015-08-05 2022-01-28 Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
US17/592,573 US20220152175A1 (en) 2015-08-05 2022-02-04 Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
JP2022142129A JP2022191218A (ja) 2015-08-05 2022-09-07 前立腺がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
CL2022003264A CL2022003264A1 (es) 2015-08-05 2022-11-21 Péptidos y sus combinaciones para uso en inmunoterapia contra el cáncer de próstata y otros
AU2023204661A AU2023204661A1 (en) 2015-08-05 2023-07-13 Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
US18/451,216 US20240016908A1 (en) 2015-08-05 2023-08-17 Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
AU2023233214A AU2023233214A1 (en) 2015-08-05 2023-09-22 Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
JP2024215091A JP2025038025A (ja) 2015-08-05 2024-12-10 前立腺がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562201289P 2015-08-05 2015-08-05

Publications (1)

Publication Number Publication Date
GB201513921D0 true GB201513921D0 (en) 2015-09-23

Family

ID=54200350

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1513921.5A Ceased GB201513921D0 (en) 2015-08-05 2015-08-06 Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers

Country Status (35)

Country Link
US (24) US9908920B2 (enExample)
EP (4) EP4324472A3 (enExample)
JP (4) JP6884752B2 (enExample)
CN (2) CN107849107A (enExample)
AR (1) AR105817A1 (enExample)
AU (8) AU2016303021B2 (enExample)
BR (1) BR112018001687A2 (enExample)
CA (3) CA3110633A1 (enExample)
CL (7) CL2018000324A1 (enExample)
CO (1) CO2018002202A2 (enExample)
CR (6) CR20180074A (enExample)
CY (1) CY1123854T1 (enExample)
DK (1) DK3331900T3 (enExample)
EA (1) EA201890440A1 (enExample)
ES (1) ES2862400T3 (enExample)
GB (1) GB201513921D0 (enExample)
HR (1) HRP20210709T8 (enExample)
HU (1) HUE053657T2 (enExample)
IL (2) IL310078A (enExample)
LT (1) LT3331900T (enExample)
MA (4) MA53452A (enExample)
MD (1) MD3331900T2 (enExample)
MX (2) MX2018001421A (enExample)
MY (3) MY202812A (enExample)
PE (2) PE20180695A1 (enExample)
PH (1) PH12018500189A1 (enExample)
PL (1) PL3331900T3 (enExample)
PT (1) PT3331900T (enExample)
RS (1) RS61713B1 (enExample)
SG (1) SG10202001660YA (enExample)
SI (1) SI3331900T1 (enExample)
TW (3) TWI829618B (enExample)
UA (1) UA125816C2 (enExample)
WO (1) WO2017021527A2 (enExample)
ZA (1) ZA201800513B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2508923A (en) * 2012-12-17 2014-06-18 Bombardier Transp Gmbh Inductive power transfer system having inductive sensing array
SI3456339T1 (sl) 2013-08-05 2022-01-31 Immatics Biotechnologies Gmbh Nova imunoterapija proti več tumorjem, kot je pljučni rak, vključno z nedrobnoceličnim pljučnim rakom
WO2017024264A2 (en) 2015-08-05 2017-02-09 Eisai R&D Management Co., Ltd. Chiral reagents for preparation of homogeneous oligomers
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
HK1258386A1 (zh) 2015-10-05 2019-11-08 Immatics Biotechnologies Gmbh 用於小细胞肺癌和其他癌症免疫治疗的肽和肽组合物
US20170199961A1 (en) 2015-12-16 2017-07-13 Gritstone Oncology, Inc. Neoantigen Identification, Manufacture, and Use
GB201609193D0 (en) 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
JP7075125B2 (ja) 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
KR102379955B1 (ko) 2016-12-08 2022-03-29 이매틱스 바이오테크놀로지스 게엠베하 짝짓기가 향상된 t 세포 수용체
WO2018213467A1 (en) 2017-05-16 2018-11-22 The Johns Hopkins University Manabodies and methods of using
US20190016802A1 (en) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Dual specificity polypeptide molecule
DE102017115966A1 (de) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Polypeptidmolekül mit verbesserter zweifacher Spezifität
ES3029080T3 (en) 2017-10-10 2025-06-23 Seattle Project Corp Neoantigen identification using hotspots
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
DE102017127984B4 (de) 2017-11-27 2019-12-05 Immatics US, Inc. Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen
US11464800B2 (en) 2018-02-09 2022-10-11 Immatics US, Inc. Methods for manufacturing T cells
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
AU2019276577B2 (en) * 2018-06-01 2025-09-11 Geneoscopy, Inc. Detection method
US10925947B2 (en) 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
TW202019955A (zh) 2018-07-31 2020-06-01 德商英麥提克生物技術股份有限公司 B*07 限制肽和肽組合的抗癌免疫治療和相關方法
US11945850B2 (en) 2018-09-17 2024-04-02 Immatics Biotechnologies Gmbh B*44 restricted peptides for use in immunotherapy against cancers and related methods
TW202024121A (zh) 2018-09-18 2020-07-01 德商英麥提克生物技術股份有限公司 A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法
WO2020167894A1 (en) * 2019-02-12 2020-08-20 Vanderbilt University Polypeptides for restoring endothelial function and methods of use thereof
US20200297768A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
PH12021552979A1 (en) 2019-05-27 2023-10-09 Immatics Us Inc Viral vectors and their use in adoptive cellular therapy
CN114303060A (zh) 2019-06-06 2022-04-08 伊玛提克斯生物技术有限公司 使用序列相似肽进行反向选择分选
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
IL295891A (en) 2020-02-24 2022-10-01 Immatics Us Inc Methods for propagating t cells for the treatment of cancer and related malignancies
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
KR20220167288A (ko) * 2020-04-14 2022-12-20 유니버시떼 드 몬트리얼 급성 골수성 백혈병(aml)에 대한 신규한 종양-특이적 항원 및 이의 용도
US20220056411A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
WO2022125507A1 (en) * 2020-12-07 2022-06-16 Iogenetics, Llc Personalized immunotherapies
WO2022147029A2 (en) 2020-12-31 2022-07-07 Immatics US, Inc. Cd8 polypeptides, compositions, and methods of using thereof
IL308258A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides
US20230024554A1 (en) 2021-06-28 2023-01-26 Immatics Biotechnologies Gmbh Method of characterizing the binding characteristics between a peptide of interest and mhc molecules
EP4113120A1 (en) 2021-06-28 2023-01-04 Immatics Biotechnologies GmbH Method of characterizing the binding characteristics between a peptide of interest and mhc molecules
CN113527435B (zh) * 2021-07-14 2022-06-07 呈诺再生医学科技(珠海横琴新区)有限公司 对前列腺癌细胞特异性识别的新型多肽及其衍生物与应用
JP2024534825A (ja) 2021-08-24 2024-09-26 イマティクス ユーエス，アイエヌシー． 条件付きリガンド交換により産生されたペプチドｍｈｃ複合体を使用する免疫細胞の選択
TW202332765A (zh) 2021-09-20 2023-08-16 美商英麥提克斯股份有限公司 用於ｔ細胞療法之ｔ細胞群體的單核球耗盡
CN118541392A (zh) 2021-09-28 2024-08-23 准星生物医药有限公司 多种形式的分子复合物
US20230192886A1 (en) 2021-11-08 2023-06-22 Immatics Biotechnologies Gmbh Adoptive cell therapy combination treatment and compositions thereof
EP4514821A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
EP4514834A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
AU2023262596A1 (en) 2022-04-28 2024-12-05 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2023215825A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy
WO2025096649A1 (en) 2023-11-01 2025-05-08 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2025137979A1 (zh) * 2023-12-28 2025-07-03 祺安（广州）生物科技有限公司 特异性多肽在制备治疗、预防前列腺癌的药物中的应用
WO2026030428A2 (en) * 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1037656A (en) 1911-11-28 1912-09-03 Thomas F Loughran Prorating-weir.
US1178658A (en) 1914-06-11 1916-04-11 United Shoe Machinery Ab Gripper mechanism for pulling-over machines.
US1165315A (en) 1914-10-31 1915-12-21 William F Cameron Governor-valve.
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
IE53176B1 (en) 1978-12-22 1988-08-17 Biogen Nv Recombinant dna molecules and their method of production
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
US6037135A (en) 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
US9340577B2 (en) * 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
JP3908271B2 (ja) 1993-03-05 2007-04-25 エピミューン，インコーポレイティド Ｈｌａ−ａ２．１結合ペプチドおよびそれらの使用
ATE183513T1 (de) 1993-06-03 1999-09-15 Therapeutic Antibodies Inc Herstellung von antikörperfragmenten
US20040157780A1 (en) * 1993-11-29 2004-08-12 Epimmune Inc. CTL inducing peptides from c-erb2 (HER-2/neu)
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US6824993B2 (en) * 1995-06-06 2004-11-30 Human Genome Sciences, Inc. Antibodies that bind human prostate specific G-protein receptor HPRAJ70
ES2203782T3 (es) 1996-01-17 2004-04-16 Imperial College Innovations Limited Inmunoterapia que utiliza linfocitos t citotoxicos (ctl).
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
DE19623825C1 (de) 1996-06-14 1998-01-08 Rottefella As Langlauf- oder Tourenskibindung
WO1998010292A1 (en) * 1996-09-06 1998-03-12 Centocor, Inc. Monoclonal antibodies specific for prostate specific antigen and methods of detecting prostate specific antigen
US7008772B1 (en) * 1997-02-25 2006-03-07 Corixa Corporation Compounds for immunodiagnosis of prostate cancer and methods for their use
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US20070020327A1 (en) * 1998-11-10 2007-01-25 John Fikes Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
WO2001025272A2 (en) 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US7361338B2 (en) 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
JP2003528584A (ja) * 1999-10-07 2003-09-30 シエーリング アクチエンゲゼルシャフト Ｐｒｏｓｔ０７ポリペプチドをコードするｄｎａ
CA2391369A1 (en) * 1999-11-12 2001-05-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
EP1261708A2 (en) * 2000-01-14 2002-12-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
AU3087801A (en) 2000-02-04 2001-08-14 Molecular Dynamics Inc Human genome-derived single exon nucleic acid probes useful for analysis of geneexpression in human breast and hbl 100 cells
US20030219806A1 (en) * 2000-02-22 2003-11-27 Millennium Pharmaceuticals, Inc. Novel 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 and 33751 molecules and uses therefor
CA2404489A1 (en) 2000-03-27 2001-10-04 Technion Research And Development Foundation Ltd. Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
JP2004504808A (ja) * 2000-03-27 2004-02-19 コリクサ　コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
CA2404541A1 (en) * 2000-03-31 2001-10-11 Curagen Corporation G-protein coupled receptors and nucleic acids encoding same
US7834146B2 (en) * 2000-05-08 2010-11-16 Monsanto Technology Llc Recombinant polypeptides associated with plants
US20030144474A1 (en) 2000-06-05 2003-07-31 Sunol Molecular Corporation T cell receptor fusions and conjugates and methods of use thereof
GB0015722D0 (en) * 2000-06-27 2000-08-16 Smithkline Beecham Sa Vaccine
US7199229B2 (en) * 2000-08-11 2007-04-03 Mount Sinai Hospital Kallikrein gene
EP1455816A4 (en) * 2000-10-19 2007-03-28 Epimmune Inc HLA CLASS I AND II BINDING PEPTIDES AND THEIR USE
US7048931B1 (en) * 2000-11-09 2006-05-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7459539B2 (en) * 2000-12-15 2008-12-02 Agensys, Inc. Antibody that binds zinc transporter protein 108P5H8
US20030109692A1 (en) * 2000-12-18 2003-06-12 Muralidhara Padigaru Novel proteins and nucleic acids encoding same
AUPR402201A0 (en) * 2001-03-27 2001-04-26 Queensland University Of Technology Polynucleotides and polypeptides linked to cancer and/or benign tumours
CA2458915A1 (en) 2001-08-31 2003-03-13 Agensys, Inc. Nucleic acid and corresponding protein entitled 205p1b5 useful in treatment and detection of cancer
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US20030223994A1 (en) 2002-02-20 2003-12-04 Hoogenboom Henricus Renerus Jacobus Mattheus MHC-peptide complex binding ligands
DE10215321A1 (de) * 2002-04-02 2003-10-23 Metagen Pharmaceuticals Gmbh Trp-p8 Splice Varianten und regulatorische RNA
KR101240547B1 (ko) * 2002-08-12 2013-03-08 더 카운실 오브 더 퀸스랜드 인스티튜트 오브 메디칼 리서어치 Ｔ-헬퍼 및 ｂ-세포 에피토프를 포함하는 신규한 면역원성리포펩타이드
EP2181595A1 (en) 2002-08-16 2010-05-05 Yeda Research And Development Company Ltd. Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
CA2500715A1 (en) 2002-10-03 2004-04-15 Epimmune Inc. Hla binding peptides and their uses
NZ539225A (en) 2002-10-09 2006-09-29 Avidex Ltd Single chain recombinant T cell receptors
ES2327229T3 (es) 2002-11-09 2009-10-27 Immunocore Ltd. Presentacion del receptor de linfocitos t.
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
GB0318096D0 (en) * 2003-08-01 2003-09-03 Queen Mary & Westfield College Vaccine
US20050053988A1 (en) 2003-08-08 2005-03-10 The Gov. Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Gene expressed in breast cancer and methods of use
WO2012079878A2 (en) * 2010-12-14 2012-06-21 Immatics Biotechnologies Gmbh Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
JP2008531025A (ja) * 2005-02-28 2008-08-14 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｄｅ１１モジュレーターの同定方法
EP1862804B1 (en) * 2005-03-14 2010-05-05 Link Genomics, Inc. Method for diagnosis of prostate cancer
ATE461215T1 (de) 2005-09-05 2010-04-15 Immatics Biotechnologies Gmbh Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden
WO2007053570A2 (en) * 2005-10-31 2007-05-10 Janssen Pharmaceutica N.V. A polypeptide complex of trpm8 and calmodulin and its uses thereof
US20130332133A1 (en) * 2006-05-11 2013-12-12 Ramot At Tel Aviv University Ltd. Classification of Protein Sequences and Uses of Classified Proteins
US20090263574A1 (en) 2008-04-21 2009-10-22 Quinn Daniel E Method of restoring an article
US8455615B2 (en) 2008-05-01 2013-06-04 Beth Israel Deaconess Medical Center Methods and compositions for prostate cancer immunotherapy
PL2119726T5 (pl) 2008-05-14 2018-04-30 Immatics Biotechnologies Gmbh Nowe i silne peptydy MHC klasy II pochodzące z surwiwiny i neurokanu
PL2172211T3 (pl) 2008-10-01 2015-05-29 Immatics Biotechnologies Gmbh Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
WO2010102157A1 (en) 2009-03-04 2010-09-10 The Regents Of The University Of California Molecular predictors of biological response to a cenpe inhibitor in cancer
WO2013040142A2 (en) * 2011-09-16 2013-03-21 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
WO2011119484A1 (en) * 2010-03-23 2011-09-29 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
SG187036A1 (en) * 2010-07-15 2013-02-28 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating genitourinary system disorders
US20120121592A1 (en) * 2010-10-13 2012-05-17 Baylor Research Institute Targeting Antigens to Human Dendritic Cells Via DC-Asialoglycoprotein Receptor to Produce IL-10 Regulatory T-Cells
EP2632955A1 (en) 2010-10-26 2013-09-04 Technion Research & Development Foundation Ltd. Antibodies which bind soluble t-cell receptor ligands
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
EP2834259A4 (en) 2012-04-02 2016-08-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES
CN105163754B (zh) 2012-09-20 2018-01-05 王荣福 前列腺特异性肿瘤抗原及其用途
WO2014071978A1 (en) 2012-11-08 2014-05-15 Roche Diagnostics Gmbh Nucleic acids encoding chimeric polypeptides for library screening
EP2808392A1 (en) 2013-05-28 2014-12-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamers and use of the aptamers in the diagnosis and treatment of cancer
TWI714869B (zh) 2013-08-05 2021-01-01 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
GB201423361D0 (en) 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
WO2016138362A1 (en) * 2015-02-26 2016-09-01 The Board Of Trustees Of The University Of Arkansas Treatment vaccine for prostate cancer
JP7236216B2 (ja) * 2015-04-23 2023-03-09 ナントミクス，エルエルシー がんのネオエピトープ
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201520566D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
BR112019028280A2 (pt) * 2017-07-04 2020-07-14 Curevac Ag moléculas de ácido nucleico
MX2023007003A (es) 2020-12-14 2023-08-18 Biontech Us Inc Antigenos especificos de tejidos para la inmunoterapia del cancer.

Also Published As

Publication number Publication date
JP2021040639A (ja) 2021-03-18
CL2018000324A1 (es) 2018-05-18
EP3331900A2 (en) 2018-06-13
MA53452A (fr) 2021-06-30
US20180344827A1 (en) 2018-12-06
SI3331900T1 (sl) 2021-08-31
JP6884752B2 (ja) 2021-06-09
AU2021202060A1 (en) 2021-04-29
CA2994771A1 (en) 2017-02-09
US20190054160A1 (en) 2019-02-21
US12076381B2 (en) 2024-09-03
PT3331900T (pt) 2021-03-18
LT3331900T (lt) 2021-03-25
IL310078A (en) 2024-03-01
AU2023233214A1 (en) 2023-10-12
MY202812A (en) 2024-05-23
CL2021001543A1 (es) 2022-01-21
UA125816C2 (uk) 2022-06-15
US20220125902A1 (en) 2022-04-28
EP3854801A3 (en) 2021-09-29
US9993539B2 (en) 2018-06-12
JP2022191218A (ja) 2022-12-27
US10376568B2 (en) 2019-08-13
US20190091311A1 (en) 2019-03-28
US10238727B2 (en) 2019-03-26
AU2021202058A1 (en) 2021-04-29
AU2021202058B2 (en) 2023-04-13
CN114395013A (zh) 2022-04-26
US20190240305A1 (en) 2019-08-08
BR112018001687A2 (pt) 2018-09-18
CR20200433A (es) 2020-10-19
HRP20210709T1 (hr) 2021-11-26
US12144852B2 (en) 2024-11-19
AU2021202057A1 (en) 2021-04-29
PE20180695A1 (es) 2018-04-23
US20220152171A1 (en) 2022-05-19
ZA201800513B (en) 2018-12-19
US10155032B2 (en) 2018-12-18
US20190275131A1 (en) 2019-09-12
CY1123854T1 (el) 2022-05-27
ES2862400T3 (es) 2021-10-07
MA46022A (fr) 2019-07-03
HUE053657T2 (hu) 2021-07-28
CR20200435A (es) 2020-10-14
US10449238B2 (en) 2019-10-22
TW201713682A (zh) 2017-04-16
AU2021202057B2 (en) 2023-04-13
MY200281A (en) 2023-12-18
JP2018529320A (ja) 2018-10-11
CR20200432A (es) 2020-10-19
AU2016303021B2 (en) 2021-02-25
US20220143163A1 (en) 2022-05-12
HRP20210709T8 (hr) 2022-03-18
US11826409B2 (en) 2023-11-28
US20240016908A1 (en) 2024-01-18
AU2016303021A1 (en) 2018-03-22
MY203318A (en) 2024-06-24
TW202106702A (zh) 2021-02-16
MA41879A1 (fr) 2019-05-31
CL2021001544A1 (es) 2022-01-21
AU2021202056B2 (en) 2023-04-06
US20170326215A1 (en) 2017-11-16
US20210275654A1 (en) 2021-09-09
US20200000900A1 (en) 2020-01-02
MD3331900T2 (ro) 2021-05-31
US12180259B2 (en) 2024-12-31
MA53680A (fr) 2021-09-29
MX2021015933A (es) 2022-02-03
CA3110640A1 (en) 2017-02-09
CL2022003264A1 (es) 2023-02-24
MA46022B1 (fr) 2021-03-31
US10478480B2 (en) 2019-11-19
US20210275653A1 (en) 2021-09-09
TWI829618B (zh) 2024-01-21
CL2021001545A1 (es) 2022-01-21
PL3331900T3 (pl) 2021-08-09
US20220143162A1 (en) 2022-05-12
RS61713B1 (sr) 2021-05-31
US20180009858A9 (en) 2018-01-11
AR105817A1 (es) 2017-11-15
US20200397878A1 (en) 2020-12-24
US10383930B2 (en) 2019-08-20
US10532091B1 (en) 2020-01-14
PE20250557A1 (es) 2025-02-24
WO2017021527A2 (en) 2017-02-09
EP4324472A2 (en) 2024-02-21
CR20200431A (es) 2020-10-14
CR20200434A (es) 2020-10-19
CO2018002202A2 (es) 2018-11-22
CA2994771C (en) 2021-04-20
US10799569B2 (en) 2020-10-13
US20220143164A1 (en) 2022-05-12
CR20180074A (es) 2018-07-23
EA201890440A1 (ru) 2018-08-31
KR20180035845A (ko) 2018-04-06
JP2025038025A (ja) 2025-03-18
US20220133870A1 (en) 2022-05-05
EP3842446A1 (en) 2021-06-30
AU2021202056A1 (en) 2021-04-29
US20180127473A1 (en) 2018-05-10
PH12018500189A1 (en) 2018-07-30
AU2021202059A1 (en) 2021-04-29
SG10202001660YA (en) 2020-04-29
MX2018001421A (es) 2018-03-15
US11786584B2 (en) 2023-10-17
US11058754B2 (en) 2021-07-13
AU2023204661A1 (en) 2023-08-10
US20210283230A1 (en) 2021-09-16
US9908920B2 (en) 2018-03-06
US12097249B2 (en) 2024-09-24
US20200323969A1 (en) 2020-10-15
EP3331900B1 (en) 2021-02-17
WO2017021527A3 (en) 2017-04-27
CL2021001542A1 (es) 2022-01-21
US20220152175A1 (en) 2022-05-19
US10500259B2 (en) 2019-12-10
JP7142957B2 (ja) 2022-09-28
EP3854801A2 (en) 2021-07-28
US12102670B2 (en) 2024-10-01
AU2021202059B2 (en) 2023-04-13
IL257331A (en) 2018-03-29
US11065315B2 (en) 2021-07-20
CA3110633A1 (en) 2017-02-09
US20170037089A1 (en) 2017-02-09
DK3331900T3 (da) 2021-03-29
CL2021001744A1 (es) 2022-02-11
US20170305982A1 (en) 2017-10-26
TW202415673A (zh) 2024-04-16
AU2021202060B2 (en) 2023-06-15
US20190374626A1 (en) 2019-12-12
EP4324472A3 (en) 2024-08-28
CN107849107A (zh) 2018-03-27

Similar Documents

Publication Publication Date Title
ZA201800513B (en) Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
IL258599A (en) New peptides and a combination of peptides used in immunotherapy against breast cancer and other types of cancer
GB201511792D0 (en) Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
ZA201707942B (en) Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
SG10202005950XA (en) Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
SG10202001665QA (en) Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
SG10202001404VA (en) Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
SG11201801344SA (en) Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
SG10202101368WA (en) Novel peptides and combination of peptides for use in immunotherapy against various cancers
ZA201707810B (en) Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
IL268278A (en) New peptides and their combinations for immunotherapy against ovarian cancer and other cancers
GB201604458D0 (en) Peptides and combination of peptides for use in immunotherapy against cancers
SG10202100295RA (en) Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201604490D0 (en) Peptides combination of peptides for use in immunotherapy against cancers
IL254081B (en) New peptides and a combination of peptides for immunotherapeutic use against pancreatic cancer and other types of cancer
ZA201801013B (en) Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
SG10202110335PA (en) Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)